Monitor upcoming medical conference presentations for additional Week 52 data and regulatory discussions later this year, which will shape the registration-directed program's scope. The $200M cash cushion removes near-term financing overhang, allowing focus on execution.
Price Chart
Executive Summary
Q32 Bio reported positive bempikibart 36-week topline results from the SIGNAL-AA Phase 2a trial in severe/very severe alopecia areata, demonstrating a 35.3% mean SALT reduction and 40% SALT-20 response rate (mITT) with a favorable safety profile. The company completed a $200M public offering in July 2026, extending cash runway through Phase 3 topline results from a planned registration-directed program expected to initiate in H1 2027. This filing confirms a major clinical catalyst and strong capitalization for a pivotal program.
Key Financial Metrics
Key Facts
- Bempikibart achieved 35.3% mean SALT reduction from baseline at Week 36 (mITT) and 40% SALT-20 response rate; well-tolerated with no new safety signals.
- Registration-directed program in severe/very severe AA expected to initiate in H1 2027 subject to regulatory discussions in H2 2026.
- Completed $200M public offering in July 2026, raising gross proceeds before expenses.
- Cash and cash equivalents were $106.3M as of June 30, 2026, plus offering proceeds expected to fund through Phase 3 topline results.
- Venture debt of $9.7M fully repaid, net debt zero at June 30, 2026.
- Net loss for Q2 2026 was $8.9M ($0.44 per share) vs $9.5M ($0.78 per share) in Q2 2025, improving due to lower R&D spend.
Financial Impact
Positive Phase 2a data and $200M offering materially de-risk the pivotal program; stock likely to re-rate on clinical success and extended runway.
Risk Factors
- Phase 2a data is open-label and may not fully predict Phase 3 success; durability and safety in longer follow-up remain key.
- Dilution from $200M equity offering pressures near-term valuation.
- Competition from approved JAK inhibitors (e.g., Olumiant) in AA; differentiation needed on safety and durability.
- Regulatory path timelines may slip; FDA feedback could require additional studies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-333813 |
| Document: qttb-20260805.htm | 0001193125-26-333813 |
| Document: 0001193125-26-333813-index-headers.html | 0001193125-26-333813 |
| Document: 0001193125-26-333813-index.html | 0001193125-26-333813 |
| Document: 0001193125-26-333813.txt | 0001193125-26-333813 |
| 8-K Data (Synthetic) | 0001193125-26-333813 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $10.91 $10.47 | ▼ −4.03% | ▼ −4.14% | $8.34 (−23.56%) |
Aug 27, 2026 5w ago | Insider Cluster | $16.15 $12.80 | ▼ −20.74% | ▼ −21.01% | $8.34 (−48.36%) |
Aug 5, 2026 8w ago | 8-K | $16.49 $15.37 | ▼ −6.79% | ▼ −7.14% | $8.34 (−49.42%) |
Jul 15, 2026 11w ago | Press Release | $15.70 $15.08 | ▲ +3.95% | ▲ +2.97% | $8.34 (+46.88%) |
Jul 14, 2026 11w ago | EFFECT | $18.46 $15.04 | ▼ −18.53% | ▼ −17.23% | $8.34 (−54.82%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.34 (−60.99%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.34 (−60.99%) |
Jun 25, 2026 14w ago | S-3 | $13.17 $13.09 | ▼ −0.61% | ▼ −2.77% | $8.34 (−36.67%) |
Jun 2, 2026 17w ago | Insider Cluster | $12.64 $11.89 | ▼ −5.93% | ▼ −2.97% | $8.34 (−34.02%) |
May 5, 2026 21w ago | 8-K | $5.14 $5.81 | ▲ +13.04% | ▲ +11.05% | $8.34 (+62.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access